DK2336120T3 - COMBINATIONS CONTAINING AMID-SUBSTITUTED INDAZOLES AS POLY (ADP-RIBOSE) POLYMERASE (PARP) INHIBITORS - Google Patents

COMBINATIONS CONTAINING AMID-SUBSTITUTED INDAZOLES AS POLY (ADP-RIBOSE) POLYMERASE (PARP) INHIBITORS

Info

Publication number
DK2336120T3
DK2336120T3 DK11157369.7T DK11157369T DK2336120T3 DK 2336120 T3 DK2336120 T3 DK 2336120T3 DK 11157369 T DK11157369 T DK 11157369T DK 2336120 T3 DK2336120 T3 DK 2336120T3
Authority
DK
Denmark
Prior art keywords
parp
adp
ribose
polymerase
inhibitors
Prior art date
Application number
DK11157369.7T
Other languages
Danish (da)
Inventor
Ontoria Jesus Maria Ontoria
Rita Scarpeli
Carsten Schultz-Fademrecht
Philip Jones
Original Assignee
Msd Italia Srl
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=37809722&utm_source=***_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DK2336120(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Msd Italia Srl filed Critical Msd Italia Srl
Priority claimed from EP08702101A external-priority patent/EP2109608B1/en
Application granted granted Critical
Publication of DK2336120T3 publication Critical patent/DK2336120T3/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing aromatic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

The present invention relates to compounds of formula (I): and pharmaceutically acceptable salts, stereoisomers or tautomers thereof which are inhibitors of poly(ADP-ribose)polymerase (PARP) and thus useful for the treatment of cancer, inflammatory discuses, reperfusion injuries, ischemic conditions, stroke, renal failure, cardiovascular diseases, vascular diseases other than cardiovascular diseases, diabetes, neurodegenerative diseases, retroviral infection, retinal damage or skin senescence and UV-induced skin damage, and as chemo and/or radiosensitizers for cancer treatment.
DK11157369.7T 2007-01-10 2008-01-08 COMBINATIONS CONTAINING AMID-SUBSTITUTED INDAZOLES AS POLY (ADP-RIBOSE) POLYMERASE (PARP) INHIBITORS DK2336120T3 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB0700432.8A GB0700432D0 (en) 2007-01-10 2007-01-10 Therapeutic compounds
US92131007P 2007-04-02 2007-04-02
EP08702101A EP2109608B1 (en) 2007-01-10 2008-01-08 Amide substituted indazoles as poly(adp-ribose)polymerase (parp) inhibitors

Publications (1)

Publication Number Publication Date
DK2336120T3 true DK2336120T3 (en) 2014-10-06

Family

ID=37809722

Family Applications (2)

Application Number Title Priority Date Filing Date
DK08702101.0T DK2109608T3 (en) 2007-01-10 2008-01-08 Amide-substituted indazoles as poly (ADP-ribose) polymerase (PARP) inhibitors
DK11157369.7T DK2336120T3 (en) 2007-01-10 2008-01-08 COMBINATIONS CONTAINING AMID-SUBSTITUTED INDAZOLES AS POLY (ADP-RIBOSE) POLYMERASE (PARP) INHIBITORS

Family Applications Before (1)

Application Number Title Priority Date Filing Date
DK08702101.0T DK2109608T3 (en) 2007-01-10 2008-01-08 Amide-substituted indazoles as poly (ADP-ribose) polymerase (PARP) inhibitors

Country Status (21)

Country Link
CN (1) CN101578279B (en)
AT (1) ATE502933T1 (en)
CR (1) CR10910A (en)
DE (1) DE602008005711D1 (en)
DK (2) DK2109608T3 (en)
ES (3) ES2509115T3 (en)
GB (1) GB0700432D0 (en)
HN (1) HN2009001260A (en)
HU (1) HUE044513T2 (en)
LT (1) LT2805945T (en)
LU (1) LUC00072I2 (en)
ME (1) ME03481B (en)
MY (1) MY147789A (en)
NI (1) NI200900135A (en)
NZ (1) NZ578256A (en)
PE (1) PE20081558A1 (en)
PT (3) PT2805945T (en)
SI (2) SI2336120T1 (en)
TW (1) TWI528961B (en)
UA (1) UA97658C2 (en)
ZA (1) ZA200903898B (en)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN106496187A (en) * 2016-09-14 2017-03-15 陕西科技大学 A kind of synthetic method for preparing PARP inhibitor Niraparib
CN106432187A (en) * 2016-09-17 2017-02-22 青岛云天生物技术有限公司 Chiral resolution method of 2-[4-(-3-piperidyl)phenyl]-2H-indazole-7-formamide
CN106432188A (en) * 2016-09-17 2017-02-22 青岛辰达生物科技有限公司 Preparation method of anti-cancer drug 2-[4-((3S)-3-Piperidinyl) phenyl]-2H-Indazole-7-Formamide
CN106632244A (en) * 2016-09-30 2017-05-10 陕西科技大学 A novel synthetic method for preparing an anticancer medicine Niraparib
CN106467513A (en) * 2016-09-30 2017-03-01 陕西科技大学 A kind of synthetic method preparing Niraparib
CN108201537A (en) * 2016-12-16 2018-06-26 苏州苏融生物医药有限公司 A kind of Ni Lapani sustained and controlled release medicaments composition and application thereof
SG11201908977SA (en) * 2017-03-27 2019-10-30 Tesaro Inc Niraparib formulations
CN109081828B (en) * 2017-06-14 2021-03-26 上海时莱生物技术有限公司 Poly (ADP-ribose) polymerase inhibitor, preparation method and application
EA202090573A1 (en) 2017-09-26 2020-09-07 Тесаро, Инк. COMPOSITIONS OF NIRAPARIBA
CN108084157A (en) * 2018-02-12 2018-05-29 安庆奇创药业有限公司 A kind of synthetic method of Ni Lapani
CN108203404A (en) * 2018-03-02 2018-06-26 上海博邦医药科技有限公司 (R) synthetic method of -3- Phenylpiperidines or/and the chiral intermediate of (S) -3- Phenylpiperidines and Ni Lapani
JP2023514794A (en) 2020-02-24 2023-04-10 フーカン（シャンハイ） ヘルス テクノロジー カンパニー、 リミテッド Anticoronavirus application of poly ADP ribose polymerase inhibitors
CN115611860A (en) * 2021-07-13 2023-01-17 上海博璞诺科技发展有限公司 Method for synthesizing nilapanib

Also Published As

Publication number Publication date
PT2109608E (en) 2011-05-30
PT2805945T (en) 2019-06-06
SI2336120T1 (en) 2014-10-30
CN101578279B (en) 2013-07-17
CN101578279A (en) 2009-11-11
HUE044513T2 (en) 2019-10-28
CR10910A (en) 2010-01-19
NI200900135A (en) 2010-08-30
ES2728199T3 (en) 2019-10-22
MY147789A (en) 2013-01-31
LUC00072I2 (en) 2018-07-04
PE20081558A1 (en) 2008-10-30
TW200836731A (en) 2008-09-16
ATE502933T1 (en) 2011-04-15
GB0700432D0 (en) 2007-02-21
HN2009001260A (en) 2012-03-26
NZ578256A (en) 2011-12-22
LT2805945T (en) 2019-06-25
DE602008005711D1 (en) 2011-05-05
SI2109608T1 (en) 2011-07-29
ZA200903898B (en) 2010-04-28
ES2509115T3 (en) 2014-10-17
TWI528961B (en) 2016-04-11
DK2109608T3 (en) 2011-07-11
ME03481B (en) 2020-01-20
UA97658C2 (en) 2012-03-12
ES2362214T3 (en) 2011-06-29
PT2336120E (en) 2014-10-01

Similar Documents

Publication Publication Date Title
DK2336120T3 (en) COMBINATIONS CONTAINING AMID-SUBSTITUTED INDAZOLES AS POLY (ADP-RIBOSE) POLYMERASE (PARP) INHIBITORS
MX2009007200A (en) Amide substituted indazoles as poly(adp-ribose)polymerase (parp) inhibitors.
MX2010005070A (en) Pyridazinone derivatives as parp inhibitors.
WO2007138351A3 (en) Pyridinone and pyridazinone derivatives as inhibitors of poly(adp-ribose)polymerase (parp)
CR20110077A (en) DIOXA-BICYCLE DERIVATIVES [3.2.1] OCTANO-2,3,4-TRIOL
EA201190158A1 (en) Derivatives of benzofuranyl for use as glucose kinase inhibitors
WO2008103277A3 (en) Nitrogen-containing heterocyclyl ketones and their use as c-met inhibitors
MX2012002179A (en) Heterocyclic oxime compounds.
EA201100503A1 (en) GLUCOSIDE DERIVATIVES AND THEIR APPLICATIONS
MX339759B (en) Compounds for the treatment/prevention of ocular inflammatory diseases.
WO2008017883A3 (en) 4-oxo-4,5-dihydropyrrolo[1,2-a] quinoxaline derivatives as inhibitors of poly(adp-ribose)polymerase(parp)
MX2012007582A (en) 4-phenoxy-nicotinamide or 4-phenoxy-pyrimidine-5-carboxamide compounds.
WO2011147951A8 (en) Cycloamino derivatives as gpr119 agonists
MA32322B1 (en) Macrocyclic Urea and Sulphonamide Derivatives as Tafia Inhibitors
MX2011013869A (en) Anthelmintic agents and their use.
GB201114389D0 (en) Novel compounds
ATE478866T1 (en) AZOLE-BASED PHOSPHODIESTERASE INHIBITORS
TH105541B (en) Indazole is replaced by amides to form inhibitors of poly (ADP-ribose) polymers (PARP).
TR201901937T4 (en) 8-methyl-1-phenyl-imidazole [1,5-a] pyrazine compounds.